Study Summary
This trial will compare continuing 5-ASA therapy versus stopping it in Crohn's disease patients who are in remission to see if there is a difference in disease flareups.
- Crohn's Disease
- Remission
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 23 Secondary · Reporting Duration: 12 months prior to enrollment and 24 months after enrollment
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
5-ASA Continuation
1 of 2
5-ASA Withdrawal
1 of 2
Active Control
Experimental Treatment
1580 Total Participants · 2 Treatment Groups
Primary Treatment: 5-ASA Withdrawal · No Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many sites have been selected to oversee this research endeavor?
"This research project is currently enrolling individuals at London Health Sciences Centre - University Hospital in London, Ontario, Taunton Surgical Center in Oshawa, Alberta, and Dr. Jesse Siffledeen Professional Medical Corporation in Edmonton, British Columbia as well as 8 further locations." - Anonymous Online Contributor
Are there any associated risks with ceasing 5-ASA use?
"The data available indicates that 5-ASA Withdrawal has a score of 3 on the safety scale, as it is currently in Phase 4 and thus approved for clinical use." - Anonymous Online Contributor
Is this experiment presently enrolling participants?
"Clinicaltrials.gov indicates that this research is actively recruiting participants, which was first published on November 20th 2017 and most recently updated on April 1st 2021." - Anonymous Online Contributor
What is the upper limit of participants enrolled in this clinical trial?
"Affirmative. The information on clinicaltrials.gov states that the trial is currently recruiting participants, beginning with the first post made on November 20th 2017 and recently edited April 1st 2021. This study seeks to enroll 1580 people from 8 different sites." - Anonymous Online Contributor